|
|
Volumn 46, Issue 9, 2011, Pages 3564-3569
|
|
Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan
a
b,c,d
b
b
b
e
e
e
e
e
e
e
a
a
|
|
Author keywords
Antihypertensive; Ester; Olmesartan; Olmesartan medoxomil; Pharmacokinetics; Prodrug
|
|
Indexed keywords
(1 ADAMANTYL)CARBONYLOXYMETHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
(1 ADAMANTYL)CARBONYLOXYMETHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TRITYLTETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
(1,2,3,4 TETRAHYDRO 2,4 DIOXOPYRIMIDIN 5 YL)METHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
(1,2,3,4 TETRAHYDRO 2,4 DIOXOPYRIMIDIN 5 YL)METHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TRITYLTETRAZOL 5 YL)PHENYL]PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 TRITYLTETRAZOL 5 YL)PHENYL)PHENYL METHYL]IMIDAZOLE 5 CARBOXYLIC ACID;
[1 (BENZOYLOXY)]ETHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
[1 (BENZOYLOXY)]ETHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TRITYLTETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
[1 (CYCLOHEXYLCARBONYLOXY)]ETHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
[1 CYCLOHEXYLCARBONYLOXY)]ETHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TRITYLTETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
DRUG METABOLITE;
ESTER DERIVATIVE;
ETHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TRITYLTETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
OCTYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TETRAZOL 5 YL)PHENYL)PHENYL METHYL]IMIDAZOLE 5 CARBOXYLATE;
OCTYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TRITYLTETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
OLMESARTAN;
PRODRUG;
TETRADECANOYLOXYMETHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TETRAZOL 5 YL)PHENYL)PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
TETRADECANOYLOXYMETHYL 4 (1 HYDROXY 1 METHYLETHYL) 2 PROPYL 1 [4 (2 (TRITYLTETRAZOL 5 YL)PHENYL]PHENYLMETHYL]IMIDAZOLE 5 CARBOXYLATE;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL TISSUE;
AREA UNDER THE CURVE;
ARTICLE;
CARBON NUCLEAR MAGNETIC RESONANCE;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG DESIGN;
DRUG HALF LIFE;
DRUG METABOLISM;
DRUG STABILITY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
IN VITRO STUDY;
LIQUID CHROMATOGRAPHY;
LIVER MICROSOME;
MALE;
MAXIMUM PLASMA CONCENTRATION;
NONHUMAN;
PLASMA;
PROTON NUCLEAR MAGNETIC RESONANCE;
RAT;
STOMACH JUICE;
ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS;
ANIMALS;
AREA UNDER CURVE;
CHROMATOGRAPHY, LIQUID;
DRUG DESIGN;
DRUG EVALUATION, PRECLINICAL;
ESTERS;
GASTRIC JUICE;
HALF-LIFE;
IMIDAZOLES;
MAGNETIC RESONANCE SPECTROSCOPY;
MALE;
MICROSOMES, LIVER;
PRODRUGS;
RATS;
RATS, SPRAGUE-DAWLEY;
TANDEM MASS SPECTROMETRY;
TETRAZOLES;
|
|
EID: 80052942627
PISSN: 02235234
EISSN: 17683254
Source Type: Journal
DOI: 10.1016/j.ejmech.2011.05.019 Document Type: Article |
|
Times cited : (7)
|
|
References (13)
|
